1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-

1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- Basic information
Product Name:1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-
Synonyms:INH 34;2-(3-(7-(3-(Ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-ylamino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide;5-[[7-[3-[Ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-1H-pyrazole-3-acetamide;AZD1152-HQPA(Barasertib);2-[5-(7-{3-[Ethyl-(2-hydroxy-ethyl)-aMino]-propoxy}-quinazolin-4-ylaMino)-2H-pyr;1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)-;2-[5-(7-{3-[ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PROPOXY}-QUINAZOLIN-4-YLAMINO)-2H-PYRAZOL-3-YL]-N-(3-FLUORO-PHENYL)-ACETAMIDE;AZD1152 HPQA
CAS:722544-51-6
MF:C26H30FN7O3
MW:507.56
EINECS:
Product Categories:Inhibitors;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Protein Kinase Inhibitors and Activators;API intermediates;Inhibitor
Mol File:722544-51-6.mol
1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- Structure
1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- Chemical Properties
Boiling point 796.7±60.0 °C(Predicted)
density 1.359±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: >15mg/mL
pka13.07±0.10(Predicted)
form powder
color white to beige
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
InChIKeyQYZOGCMHVIGURT-UHFFFAOYSA-N
CAS DataBase Reference722544-51-6
Safety Information
WGK Germany 3
MSDS Information
1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- Usage And Synthesis
DescriptionAZD1152-HQPA (722544-51-6) is a potent and highly selective inhibitor of Aurora B.1?Aurora B Ki?= 0.36 nM; Aurora A Ki?= 1,369 nM.2?It inhibits the growth of tumors in multiple cancer models.3-6?Excessive ROS generation7?and upregulated tumor suppressor miRNAs8?have been proposed as a novel mechanisms of cytotoxicity of AZD1152-HQPA.
UsesAZD1152-HQPA is a a highly selective inhibitor of aurora-B kinase. AZD1152-HQPA has been shown to inhibit osteosarcoma cell line U2-OS cells proliferation. AZD1152-HQPA was also shown to be an effective apoptosis-inducing agent in acute myeloid leukemia cell lines and primary acute myeloid leukemia cultures.
UsesAZD1152-HQPA has been used:
  • for the dose dependent inhibition of aurora kinase B (AURKB)
  • as a component to identify that, replication timing regulatory factor 1 (RIF1) and protein phosphatase 1 (PP1) are critical for the regulation of abscission timing in human cells
  • as a component to study the relevance of AURKB as a cancer therapeutic target

DefinitionChEBI: AZD-1152 is a member of the of quinazolines that is 4-aminoquinazolin-7-ol in which the amino group at position 4 has been substituted by a 5-[2-(3-fluoroanilino)-2-oxoethyl]-1H-pyrazol-3-yl group, while the hydroxy group at position 7 has been converted into the corresponding 3-[ethyl(2-hydroxyethyl)aminopropyl ether. It has a role as an antineoplastic agent and an Aurora kinase inhibitor. It is a member of quinazolines, a secondary carboxamide, a tertiary amino compound, a secondary amino compound, a member of pyrazoles, a primary alcohol, a member of monofluorobenzenes and an anilide.
Biochem/physiol ActionsAZD1152-HQPA is the active metabolite of AZD-1152, a potent selective Aurora Kinase B inhibitor. AZD1152 is 50-fold selective for Aurora kinase B over Aurora kinase C and over 1000-fold selective for Aurora kinase B over Aurora Kinase A. (IC50s: aurora-A, 1,369 nmol/L; aurora-B, 0.36 nmol/L; aurora-C, 17.0 nmol/L). It is converted in plasma to the active form AZD1152-HQPA, which has been shown to have antineoplastic activity in a variety of animal models and human cancer cell lines.
targetAurora B
References1) Mortlock?et al. (2007)?Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase; J. Med. Chem.?50?2213 2) Wilkinson?et al.?(2007)?AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis; Clin. Cancer Res.?13?3682 3) Oke?et al.?(2009)?AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo; Cancer Res.?69?4150 4) Aihara?et al.?(2010)?The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma; J. Hepatol.?52?63 5) Mori?et al.?(2011)?Effects of AZD1152, a selective Aurora B kinase inhibitor of Burkitt’s and Hodgkin’s lymphomas; Biochem. Pharmacol.?82?1252 6) Helfrich?et al.?(2016)?Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo; Mol. Cancer Ther.?15?2314 7) Zekri?et al.?(2017)?Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA; Anticancer Drugs?28?841 8) Zekri?et al.?(2018)?The Potential Contribution of microRNAs in Anti-cancer Effects of Aurora Kinase Inhibitor (AZD1152-HQPA); J. Mol. Neurosci.?65?444
1H-Pyrazole-3-acetamide, 5-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]-4-quinazolinyl]amino]-N-(3-fluorophenyl)- Preparation Products And Raw materials
MLN8054 Ethylhexylglycerin NORFLUOXETINE HYDROCHLORIDE BI 2536 N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) METHOPRENE ACID 2-HYDROXYETHYLUREA Tozasertib Alisertib (MLN8237) Hydroxyethyl Cellulose 4'-Hydroxyacetophenone MK-2206 2HCl Ethyl acetate ZM 447439 Decamethylcyclopentasiloxane Barasertib (AZD1152-HQPA)

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.